Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT03691064
Active, not recruiting Observational

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064 · tracked via the Priya Life Science Spain tracker
Sponsor
Advanced Accelerator Applications
Phase
Observational
Started
2018-11-28
Last updated
2025-12-23

Condition(s) studied

Neuroendocrine Tumors

Investigational drug(s) / intervention(s)

LUTATHERA →

LUTATHERA: Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.

Study summary

Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * adult patients (fulfilling the definition of "age of majority" per local regulations), * with unresectable or metastatic, well-differentiated, somatostatin receptor positive GEP-NETs * and who were treated with Lutathera (regardless of the quantity and number of doses administered and whatever the reasons for ending). Exclusion Criteria: * Hypersensitivity to Lutathera (active substance or any of the excipients), * presence of established or suspected pregnancy or pregnancy not excluded, * presence of kidney failure with creatinine clearance \< 30 mL/min.

Primary outcome measure(s)

  • secondary cancers: incidence of secondary cancers — up to 7 years follow-up
    incidence of secondary cancers

Trial sites (20)

FacilityCityRegionStatus
Banner MD Anderson Cancer Center Phoenix Arizona
The Ohio State University Wexner Medical Center Portland Ohio
Oregon Health & Sciences University Hospital Portland Oregon
Virginia Mason in Seattle Seattle Washington
Novartis Investigative site Clichy France
Novartis Investigative site Lyon France
Novartis Investigative site Villejuif France
Novartis Investigative site Coimbra Coimbra District
Novartis Investigative site Santiago de Compostela La Corunya
Novartis Investigative site Majadahonda Madrid
Novartis Investigative site Birmingham United Kingdom
Novartis Investigative site Cambridge United Kingdom
Novartis Investigative site Glasgow United Kingdom
Novartis Investigative site Liverpool United Kingdom
Novartis Investigative site London United Kingdom
Novartis Investigative site London United Kingdom
Novartis Investigative site London United Kingdom
Novartis Investigative site London United Kingdom
Novartis Investigative site Manchester United Kingdom
Novartis Investigative site Sheffield United Kingdom

More Advanced Accelerator Applications trials in Spain

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Active, not recruiting
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Active, not recruiting

Other trials for the same condition

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors Recruiting
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Active, not recruiting
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Active, not recruiting
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients Active, not recruiting
Spanish Series of Patients Treated With the Radionuclide Lutetium177 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03691064 on ClinicalTrials.gov ↗ ← All trials in Spain